TABLE 5.
Post-transarterial chemoembolization (TACE) features associated with mortality according to Cox regression analysis in patients with hepatocellular carcinoma
| Mortality (n=28) | Alive (n=25) | HR | 95% CI | P | |
|---|---|---|---|---|---|
| Features associated in the univariate analysis | |||||
| WHO: PR + SD versus PD | 26:2 | 23:2 | 1.07 | 0.25–4.59 | 0.9 |
| RECIST: PR + SD versus PD | 27:1 | 24:1 | 0.94 | 0.13–7.04 | 0.9 |
| EASL: PR + SD versus PD | 27:1 | 24:1 | 0.94 | 0.13–7.04 | 0.9 |
| WHO: PR versus SD + PD | 4:24 | 4:21 | 1.36 | 0.47–3.94 | 0.6 |
| RECIST: PR versus SD + PD | 4:24 | 2:23 | 2.98 | 0.98–9.04 | 0.06 |
| EASL: PR versus SD + PD | 5:23 | 3:22 | 1.08 | 0.41–2.86 | 0.9 |
| Response with 1D, cm | 3.6±3.4 | 15.7±4.8 | 0.96 | 0.93–0.99 | 0.005 |
| Response with 2D, cm2 | 5.5±5.9 | 28.5±6.8 | 0.98 | 0.97–0.99 | 0.004 |
| Response with 3D, cm3 | 4.6±8.3 | 42±10 | 0.98 | 0.97–0.99 | 0.001 |
| Reduction >3% with 1D | 13 (46) | 16 (64) | 0.48 | 0.21–0.95 | 0.04 |
| Reduction >3% with 2D | 14 (50) | 17 (68) | 0.36 | 0.17–0.80 | 0.01 |
| Reduction >3% with 3D | 15 (54) | 19 (76) | 0.31 | 0.14–0.67 | 0.003 |
| Features associated in the multivariate analysis | |||||
| Response with 3D, cm3 | 4.6±8.3 | 42±10 | 0.94 | 0.89–0.99 | 0.03 |
Data presented as n:n, mean ± SEM or n (%). Percentage of response measured as difference in size between the pre-TACE computed tomography scan and the first computed tomography scan post-TACE, expressed as percentage. 1D One dimension; 2D Two dimensions; 3D Three dimensions; EASL European Association for the Study of the Liver criteria; PD Progressive disease; PR Partial response; RECIST Response Evaluation Criteria in Solid Tumors; SD Stable disease